Cognitive Impairment in Heart Failure: A Heart Failure Society of America Scientific Statement
- PMID: 38485295
- DOI: 10.1016/j.cardfail.2024.01.003
Cognitive Impairment in Heart Failure: A Heart Failure Society of America Scientific Statement
Abstract
Cognitive impairment is common among adults with heart failure (HF), as both diseases are strongly related to advancing age and multimorbidity (including both cardiovascular and noncardiovascular conditions). Moreover, HF itself can contribute to alterations in the brain. Cognition is critical for a myriad of self-care activities that are necessary to manage HF, and it also has a major impact on prognosis; consequently, cognitive impairment has important implications for self-care, medication management, function and independence, and life expectancy. Attuned clinicians caring for patients with HF can identify clinical clues present at medical encounters that suggest cognitive impairment. When present, screening tests such as the Mini-Cog, and consideration of referral for comprehensive neurocognitive testing may be indicated. Management of cognitive impairment should focus on treatment of underlying causes of and contributors to cognitive impairment, medication management/optimization, and accommodation of deficiencies in self-care. Given its implications on care, it is important to integrate cognitive impairment into clinical decision making. Although gaps in knowledge and challenges to implementation exist, this scientific statement is intended to guide clinicians in caring for and meeting the needs of an increasingly complex and growing subpopulation of patients with HF.
Keywords: Cognition; heart failure.
Copyright © 2024 Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosures PG is supported by National Institute on Aging, grant K76AG064428, was a member of the Junior Investigator Intensive Program of the US Deprescribing Research Network, which is funded by the National Institute on Aging (R24AG064025), and has received consulting fees from Sensorum Health and personal fees for medicolegal consulting related to heart failure. RJD has received research funding from CSL Behring, Otho S.A. Sprague Memorial Institute, Chicago Department of Public Health, and Cook County Department of Public Health and has also served as an advisory board member for Abiomed and PhaseBio Pharmaceuticals. LAA reports research funding from NIH and PCORI and has received consulting fees from ACI Clinical, Boston Scientific, Cytokinetics, Novartis, Quidel, StoryHealth, and UpToDate. SJP reports research funding from the National Institutes of Health. EZG reports consulting fees from Abbott, Boston Scientific and Masimo.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous